- Home
- SES vs RNAC Comparison
SES vs RNAC Comparison
Compare SES & RNAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SES
- RNAC
- Stock Information
- Founded
- SES 2012
- RNAC 2007
- Country
- SES United States
- RNAC United States
- Employees
- SES N/A
- RNAC N/A
- Industry
- SES Auto Parts:O.E.M.
- RNAC Biotechnology: Pharmaceutical Preparations
- Sector
- SES Consumer Discretionary
- RNAC Health Care
- Exchange
- SES Nasdaq
- RNAC Nasdaq
- Market Cap
- SES 340.3M
- RNAC 316.1M
- IPO Year
- SES N/A
- RNAC 2016
- Fundamental
- Price
- SES $1.20
- RNAC $13.33
- Analyst Decision
- SES Hold
- RNAC Strong Buy
- Analyst Count
- SES 3
- RNAC 5
- Target Price
- SES $1.50
- RNAC $40.00
- AVG Volume (30 Days)
- SES 8.5M
- RNAC 83.7K
- Earning Date
- SES 08-04-2025
- RNAC 08-07-2025
- Dividend Yield
- SES N/A
- RNAC N/A
- EPS Growth
- SES N/A
- RNAC N/A
- EPS
- SES N/A
- RNAC N/A
- Revenue
- SES $7,833,000.00
- RNAC $34,173,000.00
- Revenue This Year
- SES $916.42
- RNAC N/A
- Revenue Next Year
- SES $151.67
- RNAC N/A
- P/E Ratio
- SES N/A
- RNAC N/A
- Revenue Growth
- SES N/A
- RNAC 31.91
- 52 Week Low
- SES $0.20
- RNAC $8.46
- 52 Week High
- SES $2.53
- RNAC $26.50
- Technical
- Relative Strength Index (RSI)
- SES 66.13
- RNAC 60.40
- Support Level
- SES $1.08
- RNAC $11.80
- Resistance Level
- SES $1.28
- RNAC $13.91
- Average True Range (ATR)
- SES 0.09
- RNAC 1.10
- MACD
- SES 0.03
- RNAC 0.03
- Stochastic Oscillator
- SES 76.67
- RNAC 53.04
About SES SES AI Corporation
SES AI Corp is a developer and manufacturer of high-performance, AI-enhanced Lithium-Metal (Li-Metal) and Lithium-ion (Li-ion) rechargeable battery technologies for electric vehicles (EVs), Urban Air Mobility (UAM), drones, robotics, Battery Energy Storage Systems (BESS) and other applications. It includes Software and Hardware products that are EV, UAM, Drone, Molecular Universe, and Avatar.
About RNAC Cartesian Therapeutics Inc.
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. The company leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function.